

November 15, 2016



ITUS Demonstrates Efficacy of its Cchek(TM) Early Cancer Detection Platform with 6 Additional Cancer Types

LOS ANGELES, CA -- (Marketwired) -- 11/15/16 -- ITUS Corporation ("[ITUS](#)") (NASDAQ: ITUS), today announced that it has successfully utilized its proprietary Cchek™ early cancer detection platform to identify the presence of 6 additional cancer types, including Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), and Vulvar Cancer (cancer of the Vulva).

"Although it is still too early to be certain, with each additional cancer type that we demonstrate efficacy, we get one step closer to proving that Cchek™ could eventually become a 'pan-cancer' diagnostic that works with all types of cancer," said Robert Berman, the President and CEO of ITUS. "Success with any one of the big cancer killers like Breast Cancer or Lung Cancer would be cause enough for excitement, but based upon our preliminary results, we believe that Cchek™ has the potential to be transformative in the diagnosis of many and possibly all cancers."

Prior to today's announcement, the company previously announced success in detecting 7 different cancer types, including Breast Cancer, Lung Cancer, Colon Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Thyroid Cancer, and Pancreatic Cancer, bringing the number of cancer types detected using its Cchek™ platform to 13. The company expects to release preliminary data from its Cchek™ biomarker study in the coming weeks, and will continue to accumulate and evaluate additional patient data, and perform such other testing as is necessary to begin the regulatory approval process.

ITUS Corporation

[ITUS](#) funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

[ITUS Corporation](#): FOCUSED ON INNOVATION™

Contact:

Dean Krouch

310-484-5184

dkrouch@ITUScorp.com

Source: ITUS Corporation